Cell Therapeutics Inc(NASDAQ:CTIC) stock declined 3.69% to $2.87. The company last week said that it has launched its recently approved oncology drug Pixuvri in the EU. Pixuvri was approved by EU regulators in May for the treatment of aggressive B-cell non-Hodgkin lymphoma, or NHL. Approximately 37,000 new cases of aggressive B-cell NHL are diagnosed in the EU every year.
Can CTIC Recover After The Recent fall? Find Out - goo.gl/Ruoc3